FASN and cancer: Dysregulated lipogenesis, driven by fatty acid synthase (FASN) overexpression, promotes tumour progression and is associated with poor clinical outcomes across multiple cancer types, including ovarian and other malignancies [17, 18, 19, 20, 21, 22].